Friday said it had settled a patent litigation case in its favor.
The case pitted Mylan and its Spain-based development partner, Esteve Quimica, vs. Kremers Urban Development Company and Schwarz Pharma's other U.S. subsidiaries dating back to 2002.
Under terms of the settlement, Mylan and Esteve Quimica will receive a total of $50 million from Kremers Urban. Mylan's share is $37.5 million, part of which will cover legal fees and other costs.
In a statement Mylan said: The settlement resolves both suits and any claims with regard to each company's omeprazole and other proton pump inhibitor process and formulation patents on a world-wide basis, and also ends a related arbitration proceeding in Spain.
Mylan shares fell 14 cents, or 0.7%, to $21.
It's been an eventful week for the Pittsburgh-based Mylan.
On Thursday, the company said it got the go ahead to make a generic version of
thyroid-replacement treatment Synthroid.
In another development, Mylan Wednesday said it will sue the Food and Drug Administration over the approval of a pain relief drug and suspended annual earnings guidance as a result.
The lawsuit will seek to restore final approval for its fentanyl transdermal system on the grounds that the FDA had "acted contrary" to two U.S. laws, its published regulations and the legal precedent.
At issue is Mylan's efforts to sell a generic version of Duragesic, a pain relief patch marketed by Janssen Pharmaceutica L.P., a unit of
Johnson & Johnson
The FDA recently granted Janssen additional patent protection, delaying the introduction of Mylan's product by another six months.